Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

• Status: Completed
• Trial end date: 2013-09-01

Summary

The purpose of this study is to determine the effects of tivantinib on the pharmacokinetics of omeprazole, s-warfarin, caffein, midazolam, or digoxin in patients with cancer.

• Phase: Phase 1

Details

• Lead Sponsor: Daiichi Sankyo Inc.; Daiichi Sankyo, Inc.
• Collaborator: Medpace, Inc.
• Treatments: Caffeine; Digoxin; Midazolam; Omeprazole; Vitamin K; Vitamins; Warfarin